Manzanita Trees In Northern Arizona

BLOG OPHTHALMOLOGY CEUTA EYES: PRECAUTIONS IN CATARACT SURGERY IN PATIENTS WITH TREATMENT EYE OPHTHALMOLOGY


www.qxeyes.com

The use of tamsulosin within 14 days of cataract surgery has been associated with serious postoperative problems, according to an article published in the Journal of the American Medical Association . X

tamsulosin in alpha-adrenergic blocker that has been commonly prescribed to treat benign prostatic hyperplasia, and which has been described that increases the risk of intraoperative complications during cataract surgery. But until recently were not described the potential postoperative complications after use of tamsulosin versus other alpha-blockers used in the treatment of prostate disease. X

The paper has compared the complications between patients treated with tamsulosin versus other alpha-blockers, and the existence of recent exposure to tamsulosin (14 days prior) or from 15 to 365 days earlier, on a set of 3550 patients treated with tamsulosin and 7426 treaties with other alpha-blockers. X

adverse effects have been reported in 284 patients (0.3%), including 100 cases of suspected endophthalmitis, 175 cases of detention crystal fragments, 35 detachments and 26 cases of retinal detachment and retention of fragments. These effects were not observed with the use of other alpha-blockers. X

The study concludes that "exposure to tamsulosin in the 14 days prior to cataract surgery has been shown related to increased incidence of serious postoperative complications eye, whereas no association was found with other alpha-blockers used to treat benign prostatic hypertrophy.
X
Since the combination of cataract surgery and treatment with tamsulosin is relatively common for patients should be warned of potential risks, and the ophthalmologist must plan and schedule the surgery as compared to potential intraoperative complications (floppy iris syndrome) and postoperative. To this end, different strategies have been proposed as strong cycloplegic dilation (atropine or homatropine), high density viscoelastic agents, low flow intraoperative use of iris retractors or other stabilization procedures or pupillary dilation.
X
JAMA. 2009; 301:1991-1996, 2044-2045. X

Basic information and guidance. To personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Tv Center Pro Windows 7

TAMSULOSIN CEUTA: NEW PERSPECTIVES GENE THERAPY IN THE EYES OF OPHTHALMOLOGY

A recent study by researchers at the University of Washigto n has been estaurar color vision in adult monkeys with impaired perception of red and green.
x
The study was published in the journal "Nature" ("Colour blindness corrected by gene therapy"), and its makers claim that the treatment could work in humans, says Jay Neitz, leader of the team.
x
The study represents a significant advance, since until now the scientific community does not think it was adult brain can be manipulated to correct color blindness. Thus, it is considered only during the first years of life, when there is greater "plasticity" cerebral, it was possible to add new sensory information to people, which may improve vision.
x
Neitz teacher team managed to introduce therapeutic genes into cells in the retina of the eye of an adult male monkey, containing the DNA code needed for cells could distinguish between red and green.
x
therapy seems to have been a success, since the treated monkeys were able to pass tests of color, being able to correctly identify the red forms that appeared in green funds.
x
Animals received treatment for two years, scientists have managed to keep its vision corrected from those tests.
x
Still to assess what might be the long-term effects of treatment.
x
As explained by Dr Winfried Amoaku, an expert in ophthalmology at the University of Nottingham UK (United Kingdom), speaking to the BBCA, said the research could benefit approximately 7% of men and 1% de las Mujeres born with vision problems.
x
basic information and guidance. For a personalized information see su ophthalmologist.
x

OJOS of Ceuta. Innovating in Ophthalmology.
Ophthalmological Center DR. Medina Catoira

Ojos de Ceuta - Innovating in Ophthalmology Ophthalmological Center Dr. Medi Catoira

Denise Milani akiba-online

DALTON CEUTA: PRECAUTIONS IN CATARACT SURGERY IN PATIENTS with tamsulosin

www.qxeyes.com

A retrospective study published in the Journal of the American Medical Association shows the association between the use of tamsulosin , a drug commonly used in the treatment of benign prostatic hypertrophy , and the presence of serious complications during and extraoperatorias during cataract surgery.
X
The study shows that patients who receive or have received recent treatment with tamsulosin in the 14 days prior to surgery have a significantly higher incidence of complications in surgery cataract, increased incidence that it has been observed with other alpha-blockers used in the treatment of benign prostatic hypertrophy (BPH) .
X
Tamsulosin is a drug blocking alpha-adrenergic receptor that is frequently prescribed for the treatment of prostatic hypertrophy. Given its frequent use, patients should be warned of the perioperative risks and the ophthalmologist must be prepared for possible complications, since the suspension of treatment before surgery so does not reduce the risk of complications such as intraoperative floppy iris syndrome (IFIS).
x
To reduce potential intraoperative complications (IFIS, capsular rupture, vitreous loss, retinal detachment, ..) have proposed pharmacologic strategies and instruments such as the use of cycloplegic powerful (atropine, homatropine), denser viscoelastic under fluid flow, iris retractors, pupil dilator rings and expanders.
x
Both the patient and the ophthalmologist should be aware, be advisable for the surgeon to warn the patient before surgery if you are undergoing treatment with Tamsulosin for prostatic hypertrophy (Omnic, Omnic Geese, Urolosin, Urolosin geese) .
x
JAMA. 2009; 301:1991-1996, 2044-2045.

x
Basic Information and indicative. For personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN
Eyes

Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira